# OnCo record ltz-232 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ltz-232/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ltz-232" ;
  schema:name "LTZ-232"@en ;
  schema:description "LTZ-232 is an experimental bispecific antibody from LTZ Therapeutics, in phase 1 trials for metastatic colorectal cancer, other advanced solid tumours and malignant ascites."@en ;
  schema:url <https://onco.cc/drugs/ltz-232/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.ltztherapeutics.com/html/news/146.html>, <https://www.ltztherapeutics.com/html/news/146.html>, <https://www.ltztherapeutics.com/pipeline/index.html>, <https://clinicaltrials.gov/search?intr=LTZ-232> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Bispecific antibody (myeloid cell engager)" ;
  onco:cancers <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:targets <https://onco.cc/targets/epcam/> ;
  onco:companies <https://onco.cc/companies/ltz-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07878988/> .